Savara Inc. SVRA R2K

Q: What is the current share price of Savara Inc. (SVRA)?

As of 2026-07-14 21:23 PDT, Savara Inc. (SVRA) trades at $5.69 on NasdaqGS. Its 52-week range is $2.26 to $6.94.

Q: What is the market capitalisation of SVRA?

Savara Inc. (SVRA) has a market capitalisation of $1.17B on NasdaqGS.

Q: What is the P/E ratio of SVRA?

SVRA trades at a trailing price-to-earnings (P/E) ratio of -10.16. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 7.58.

Q: What is the return on equity (ROE) of SVRA?

SVRA has a return on equity (ROE) of -79.95%. Its return on capital employed (ROCE) is -53.02%.

Q: Is SVRA a good stock to buy?

This page provides a data-driven analysis of Savara Inc. (SVRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.savarapharma.com

Company Profile ↓

$5.69

+126.69% 1Y

Mkt Cap$1.17B

P/E-10.16

P/B7.58

52W High$6.94

52W Low$2.26

Book Value$0.69

EPS (TTM)$-0.56

Company Overview

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Recent Developments

5-Year Trend Long-term compounding — revenue CAGR -7.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-7.73%
1 Year:	-

Stock Price Performance

1 Year:	+126.69%
6 Months:	-2.07%
3 Months:	-3.89%
1 Month:	+7.97%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 73% of range

$2.26 $6.94

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)47.21 · Neutral

Price Performance

1M+7.97%

3M-3.89%

6M-2.07%

1Y+126.69%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -7.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-10.16

Industry PE

25.41

Forward P/E

-19.35

PEG Ratio

Book Value

$0.69

Price to Book

7.58

P/S

4,194.23

EV/EBITDA

-8.71

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-7.73%

Profit 5Y

Revenue (YoY)

Earnings (YoY)

Profitability & Returns

ROCE

-53.02%

ROE

-79.95%

ROA

-40.53%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.15

EPS (TTM)

$-0.56

Balance Sheet & Liquidity

Debt/Equity

0.17

Quick Ratio

13.21

Current Ratio

13.47

Debt

$30.11M

Total Assets

$221.65M

Current Assets

Working Capital

Ownership

Promoter Holding

2.57%

Chg in Prom Hold

FII / Inst Holding

104.22%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$1.17B

Total Revenue (TTM)

$257.00K

EBITDA

$-133.17M

Free Cash Flow

$-57.65M

Operating Cash Flow

$-106.89M

Shares Outstanding

204.93M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SVRA Savara Inc. R2K	5.69	-10.16	$1.17B	0.00%	-53.02%	-79.95%	-7.73%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	256.00K	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-7.35M	-9.65M	-10.18M	-9.83M	-9.71M	-1.69M	-1.98M	-3.23M	-4.04M	-4.77M	-9.34M	-6.54M	-9.30M	-32.11M	-11.91M	-12.78M	-13.25M	-12.92M	-22.15M	-12.44M	-31.51M	-16.24M	-9.26M	-10.79M	-10.41M	-10.45M	-9.97M	-8.05M	-9.38M	-10.54M	-12.11M	-12.22M	-18.04M	-22.48M	-23.19M	-26.36M	-28.43M	-31.44M	-30.25M	-38.99M
Net Income	-7.31M	-9.62M	-10.15M	-9.91M	-10.16M	-1.68M	-2.05M	-3.23M	-3.97M	-4.97M	-11.50M	-6.82M	-6.50M	-26.85M	-11.59M	-12.56M	-10.51M	-12.11M	-21.94M	-12.40M	-31.72M	-15.42M	-9.39M	-11.06M	-10.22M	-10.94M	-10.55M	-8.30M	-9.16M	-10.39M	-10.56M	-11.44M	-16.60M	-20.35M	-22.24M	-24.25M	-26.64M	-30.40M	-29.56M	-37.28M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.07	-0.07	-0.05	-0.06	-0.07	-0.07	-0.07	-0.10	-0.11	-0.12	-0.11	-0.12	-0.14	-0.14	-0.15
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	488.96K	-	0	0	0	54.00K	400.00K	0	-	0	257.00K	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	488.96K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-8.54M	-13.40M	-15.63M	-21.54M	-29.28M	-5.92M	-10.95M	-29.96M	-70.05M	-79.03M	-49.30M	-41.48M	-38.84M	-60.01M	-103.20M	-123.55M
Net Income	-1.98M	-1.20M	-1.06M	-3.70M	-16.34M	-2.11M	-2.33M	-6.70M	-24.78M	-29.33M	-22.14M	-26.65M	-11.33M	-8.45M	-13.26M	-15.56M	-21.48M	-28.70M	-9.00M	-10.92M	-29.80M	-61.52M	-78.17M	-49.62M	-43.01M	-38.15M	-54.70M	-95.88M	-118.84M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.32	-0.25	-0.33	-0.48	-0.53

Balance Sheet (Annual)

Figures in USD.

Metric	Jun 1996	Dec 1996	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28.49M	61.86M	46.97M	55.25M	70.50M	54.22M	28.93M	159.63M	152.29M	136.20M	97.75M	176.60M	139.78M	177.56M	212.88M	253.44M
Total Equity	0	-272.62K	382.21K	-525.26K	-1.23M	14.61M	-638.49K	-852.73K	4.12M	12.39M	-7.83M	19.96M	31.03M	6.00M	6.67M	26.69M	56.78M	41.79M	47.81M	-18.30M	-27.33M	-35.88M	119.31M	108.22M	101.70M	64.38M	144.50M	107.78M	140.37M	171.45M	203.13M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.67M	27.98M	43.57M	22.50M	25.68M	12.69M	16.68M	13.37M	22.12M	24.30M	49.80M	22.88M	34.01M	52.10M	26.59M	15.13M	33.18M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.10M	17.32M	26.08M	26.35M	26.62M	29.91M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.80M	5.08M	5.18M	7.44M	11.84M	30.33M	20.95M	40.32M	44.07M	34.51M	33.36M	32.10M	32.00M	37.19M	41.43M	50.30M
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.80M	2.47M	2.57M	4.83M	8.44M	23.17M	3.46M	6.01M	7.25M	10.88M	8.17M	14.66M	5.87M	10.60M	14.72M	20.40M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-8.34M	-13.47M	-13.92M	-17.79M	-	-	-	-28.23M	-39.27M	-45.12M	-39.84M	-40.08M	-34.55M	-51.06M	-89.09M	-101.04M
Investing Cash Flow	-24.13K	-7.54M	-7.17M	-4.77M	-	-	-	-69.11M	-13.62M	15.74M	9.05M	-69.46M	52.65M	-57.12M	-39.94M	-18.44M
Financing Cash Flow	27.68M	36.60M	740	25.74M	-	-	-	106.09M	55.19M	54.91M	3.69M	120.81M	87.00K	82.78M	117.58M	137.81M
Capital Expenditure	-28.51K	-411.76K	-266.18K	-47.00K	-147.00K	-165.00K	-8.00K	-495.00K	-141.00K	-148.00K	-47.00K	-57.00K	-9.00K	-296.00K	-25.00K	-22.00K
Free Cash Flow	-8.37M	-13.88M	-14.19M	-17.84M	-	-	-	-28.73M	-39.42M	-45.27M	-39.88M	-40.14M	-34.56M	-51.36M	-89.11M	-101.06M

Ratios (Annual)

Figures in %.

Metric	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	100.0%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,746.5%	-	-	-	-	-10,968.5%	-2,737.0%	-	-	-	-19,182.9%	-	-	-	-	-
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,728.3%	-	-	-	-	-16,664.8%	-2,730.8%	-	-	-	-19,305.4%	-	-	-	-	-
ROE %	-517.9%	229.3%	85.6%	-25.3%	2,559.0%	246.9%	-56.6%	-54.1%	316.6%	-147.0%	-71.3%	-444.5%	-169.7%	-31.7%	-23.4%	-37.2%	-44.9%	156.9%	32.9%	30.4%	-25.0%	-56.8%	-76.9%	-77.1%	-29.8%	-35.4%	-39.0%	-55.9%	-58.5%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	-	-	-32.0%	-22.6%	-35.2%	-42.7%	-47.2%	-19.1%	-43.0%	-19.5%	-48.3%	-63.1%	-55.0%	-25.6%	-29.0%	-35.9%	-52.1%	-53.0%

Shareholding Pattern

Insiders

2.57%

Institutions

104.22%

Public Float

106.98%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	NEA Management Company, LLC	11.94%	24.47M	$151.60M
2	Bain Capital Life Sciences Investors, LLC	8.59%	17.60M	$109.04M
3	Venrock Adviser, LLC	6.71%	13.74M	$85.12M
4	Deerfield Management Company, L.P	6.62%	13.57M	$84.06M
5	TCG Crossover Management, LLC	6.03%	12.36M	$76.58M
6	Blackrock Inc.	5.51%	11.29M	$69.95M
7	Frazier Life Sciences Management, L.P.	4.74%	9.72M	$60.22M
8	Polar Capital Holdings PLC	4.66%	9.54M	$59.11M
9	Vanguard Capital Management LLC	3.80%	7.78M	$48.22M
10	Nantahala Capital Management, LLC	3.58%	7.34M	$45.50M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SVRA

Google News hu, 09 Jul 2026

SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNb3RnZU5MYnh3YVI2V2ZTOXU4cUtfRF85YnpOU1JCaElDUXhCU3RuZzJxWWJYVms4S1FOMVo3ekliNlRQRGhWck90Q0ZKVElvWUFBNGNDQ2p5UzEwenJlREU5M0pDRFE0Vkw2TTNna3RsQmxsUXAzMGdEZkpiTTFxbnVER25xYU9yS0tmRk…

Google News Wed, 08 Jul 2026

Savara (SVRA) Stock May Trade At A Premium On Pipeline Expectations - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOdmFaZkM3ZUotbmJXNUNmUWs1TjR1cWZDdVhqV1ZYU2VTajRHV3FESzd0U3JqaExacWJGaTVBQWlMdndaM09BRTZoZUxVdk91TXZwSTA1b1NhNWNXTG8zOU9NWDRWb25tTFpaMWVDRnE5WnpnMXJYSm41NmpDSXgzQjhlUDhzWkNsOHUwTF…

Google News Fri, 26 Jun 2026

SVRA Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5XWDNfcjFRRlFsc2lOSVh2YzFWZW82N0dYZDlaTzhQN1FCMlJ3X2NrVDI5SG51aC11X0JVc3pGeWh1NlRmZWFndU41OXJJcjhVQ0ZKblV3MG04dkczdmpDZEJKelBfOFZOUjhrXzFxNkVqRFduQnQxTld3?oc=5" target="_blank">SVR…

Google News ue, 23 Jun 2026

Insider Sale: Chief Financial Officer of $SVRA Sells 394,528 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWWtjbDNkd1Y1MTRwZ0d0aGF5dTNGRTh1NGxsR0JIdzduakFuRVJVTEoxd280SVVheWhEYXJpaDhnWGdvWXpPZVIta29YT2ZRaXh2eF9pYUNaX0htZWctQmF1WEZ2dm1aUkhiQkl1NUs3cUZqMndWVWNqZ09ZaG0tS2FyX0hjT1ZRejR3Ql…

Google News Sun, 26 Apr 2026

Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOWlpJMkplcFJnemlBQXpTbTYzSXR1X3Q5TEtheldUTExYT1RaWXNRZzJKUHl1MElCd2Z0RVdqZldVX0JnQktJU0gwTkRJT3F3WkEtc1prSG9mdWstcUJOck5FUGZzTkR6b3V2Ry01M2xRWS05UzNUaDljakxORVlMZEJna0ZQRHJKaGtJQl…

Google News Mon, 22 Jun 2026

Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQQVZ1VzllempzNllmU3liT05MQzlGSURVbEdzbk4wdGdpYkl4aF9FX3JVUG16Zkc3emZ1UFQzejhWUDJERDA3MGYtb09Va0RiQ2lZci1PYTNycmJkRXNPWEgzdEFPV3pNdU9vMHdmaXNYMTZKMXNiMkQ0NWFtOGRnelluY3pIU2NzdGZaNT…

SVRA — Frequently Asked Questions

What is the current share price of Savara Inc. (SVRA)?

As of 2026-07-14 21:23 PDT, Savara Inc. (SVRA) trades at $5.69 on NasdaqGS. Its 52-week range is $2.26 to $6.94.

What is the market capitalisation of SVRA?

Savara Inc. (SVRA) has a market capitalisation of $1.17B on NasdaqGS.

What is the P/E ratio of SVRA?

SVRA trades at a trailing price-to-earnings (P/E) ratio of -10.16. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 7.58.

What is the return on equity (ROE) of SVRA?

SVRA has a return on equity (ROE) of -79.95%. Its return on capital employed (ROCE) is -53.02%.

Is SVRA a good stock to buy?

This page provides a data-driven analysis of Savara Inc. (SVRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Savara Inc. SVRA R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy - Stocktwits

Savara (SVRA) Stock May Trade At A Premium On Pipeline Expectations - simplywall.st

SVRA Forecast — Price Target — Prediction for 2027 - TradingView

Insider Sale: Chief Financial Officer of $SVRA Sells 394,528 Shares - Quiver Quantitative

Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Yahoo Finance

Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan

SVRA — Frequently Asked Questions

What is the current share price of Savara Inc. (SVRA)?

What is the market capitalisation of SVRA?

What is the P/E ratio of SVRA?

What is the return on equity (ROE) of SVRA?

Is SVRA a good stock to buy?

Explore More